An Open-Label,Randomized Phase 3 trial of Nivolumab, or Nivolumab plus Ipilimumab, versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Clinical Trial Grant
Awarded By
Bristol-Myers Squibb Company
Start Date
November 1, 2015
End Date
May 21, 2018
Awarded By
Bristol-Myers Squibb Company
Start Date
November 1, 2015
End Date
May 21, 2018